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As we near the decade’s 
end, the Department of 
Medicine continues to 
break new ground and 
celebrate numerous 
successes. Some of 
our achievements are 
behind-the-scenes, like the work of our intrepid 
researchers at the Center for Translational 
Medicine. Other milestones are making headlines, 
such as the 25th anniversary of the region’s first 
liver transplant. 
Our lead story announces our recent Length-of-Stay 
Initiative, which is promoting the most effective, 
efficient care for our patients while improving 
administrative and communication processes and 
reducing costs. We also feature the research of Dr. 
Rabinowitz, in gene therapy, and Dr. Peppel, in 
vascular remodeling. For our clinical activities, we 
spotlight Endocrinology’s new protocols for our 
diabetic inpatients and Dr. Kane’s leadership for 
Residents as well as Pulmonary/Critical Care. We 
are enthusiastic about the new career pathways 
designed to train residents in new, customized ways.
Much of this work is possible thanks to our 
generous donors, such as Mr. Scarperi (featured 
on page 5). With their help we look forward to 
the next 10 years of providing excellent patient 
care, first-rate medical education, and significant 
research outcomes. Please also visit our website 
at www.jefferson.edu/medicine for more in-depth 
articles and updates.
Arthur M. Feldman, MD, PhD
Magee Professor of Medicine and 
Chairman of the Department
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Inpatient care at Jefferson, like at all academic 
medical centers — which treat patients while 
they train doctors — is complex, with dozens 
of key players, both at the patient’s bedside 
and behind the scenes. In September 2008, 
the Department of Medicine began a rigorous 
process for improving the management of 
patients’ length of stay (LOS). The goals are to 
maintain first-rate quality of care, identify 
barriers hindering an efficient process, and 
create systems to support a streamlined approach.
“Decreasing LOS for our patients serves two 
important ends,” explains Karen Javie, RN, MSN, 
Vice President for Strategic Initiatives at the 
University. “First, shorter hospital stays are in 
our patients’ best interest. Research has shown 
the longer the stay, the greater the incidence 
of developing additional health risks and 
complications. Second, it reduces medical costs 
to the patient, insurer, physician, and hospital — 
all of which are critical in the current climate 
of escalating health care costs,” Ms. Javie says. 
“The Jefferson leadership recognized that it 
was time to make the necessary cultural shift.” 
As leader of the initiative, Arthur Feldman, 
MD, PhD, the Magee Professor and Chair of 
Medicine, drew on expertise from the Chartis 
Group, a health care consulting firm and 
formed a multidisciplinary oversight committee 
to develop a plan to tackle this formidable task. 
He also convened five subcommittees: 
Physician Leadership, Information Technology, 
Evidence-Based Medicine, Resources, and 
Non-Teaching Hospitalists. These teams 
completed the initial work by December 2008, 
and Dr. Feldman delivered a Grand Rounds in 
January 2009, when he shared the outcomes 
and subcommittee recommendations. 
THOMAS JEFFERSON UNIVERSITY
Continued on page 7
“Huddles” are being used to streamline inpatient 
care and reduce patients’ length of hospital stay. 
Attendings, house staff, nurse managers, therapists, 
and case managers convene each morning to improve 
communications and efficiency. 
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2C e n t e r  f o r  T r a n s l a t i o n a l  M e d i c i n e
Karsten Peppel, PhD, examines a blood vessel through a macro-view fluorescence 
microscope in researching the role of inflammation in vascular remodeling.
Molecular biologist Karsten Peppel, PhD, 
Associate Professor, joined the Center for 
Translational Medicine in 2006. He came 
to the U.S. from Germany in 1984, to study 
at SUNY Albany and then trained at Duke 
University. His lab studies the role of 
inflammation in vascular remodeling. 
Can you explain vascular remodeling? 
The term describes how the blood vessel 
structure changes after injury. If you tear a 
Learning from How Blood Vessels Heal
muscle, or a blood clot forms in an artery, 
blood flow is cut off. Small vessels that 
connect major arteries (called collaterals) 
open up and undergo structural changes to 
expand and strengthen and form new vessels 
that provide more blood to the injured tissue. 
In diseases such as peripheral arterial disease — 
common in type-2 diabetes — the collaterals 
do not open up adequately, there are not 
enough new blood vessels, and problems 
like necrosis and gangrene can set in. We 
investigate these and other instances of 
dysfunctional vascular remodeling.
What is the role of inflammation? 
Acute inflammation protects organisms from 
injury and infection, but chronic inflamma-
tion drives vascular dysfunction and seems to 
be a common thread that runs 
through many chronic diseases, 
including Alzheimer’s, type-2 
diabetes, atherosclerosis, and 
cardiac disease. Chronic vas-
cular inflammation can lead 
to the formation of clots that 
can cause heart attacks.  
What mediates the 
inflammation?  
We are studying Tumor 
Necrosis Factor (TNF), 
which has two receptors 
(TNFR1 and TNFR2). We 
are investigating how these 
receptors contribute to 
vascular remodeling following 
injury. We already knew that 
signals from the TNFR1 could 
be toxic to endothelial cells (which line the 
blood vessels, keep blood flowing, and prevent 
clotting). We were surprised that TNFR1 also 
supports the growth of smooth muscle cells, 
which underlie the endothelium and can 
strengthen the vessels after injury. TNFR2 
can even aid endothelial cells after injury.   
Targeting Viruses That Work Against Heart Failure
Cardiovascular disease accounts for nearly 40 
percent of all deaths that occur in the U.S. each 
year, and the cost to our economy is a staggering 
$394 billion. Joseph E. Rabinowitz, PhD, 
Assistant Professor at the Center, devotes 
his research to the study and creation of 
vectors (such as viruses) that are essential to 
the delivery of a progressive treatment called 
gene therapy. 
Dr. Rabinowitz and Center Director Walter 
Koch, PhD, have the ambitious task of 
removing disease-causing genes and inserting 
therapeutic ones in their place. Dr. Koch has 
focused on how to use gene transfer to treat 
cardiovascular disease, and he has successfully 
used the technique to halt heart failure in 
mice. The Center focuses on replicating this 
research in other animals, so that it may 
ultimately be approved for clinical research 
in humans. “One of the keys to breaking the 
clinical barrier with gene transfer,” explains 
Dr. Rabinowitz, “is finding a safe and effective 
mechanism for gene delivery to the heart.” 
His work is to create that vector. 
Why use viruses?  
Viruses — once they have been genetically 
altered to deliver normal DNA — are 
vectors currently used in gene therapy. 
Dr. Rabinowitz and his lab are researching 
the use of the adeno-associated virus (AAV), 
which causes very little immune response 
in humans. AAV is first modified with the 
desired therapeutic gene, and then it infects 
the targeted cells with the genetic material that 
will help the cell counteract the disease. 
Which viruses to use?  
Using basic research, Dr. Rabinowitz 
identifies and creates specific viruses for these 
incredibly precise purposes. His team injected 
mice in their tail veins with a version of AAV 
containing the gene for firefly luciferase 
(which causes fireflies to glow). They then 
You also conduct research on vein grafts.
In a coronary artery venous bypass graft, 
which uses a leg vein to bypass the blocked 
artery, these veins have 40–50% failure rate 
after two years. There are few options for 
patients with blocked vein grafts. Nature 
simply has not designed veins to handle the 
same kind of stress that arteries can handle. 
So the vein develops more smooth muscle cells, 
to have a firmer structure. If this process stops 
at the right time, the vein remains open and 
can handle arterial blood flow. But if the vein 
wall becomes too thick, it eventually blocks 
the blood flow. This is where our discovery 
of the opposing effects of TNF receptors in 
vascular remodeling became so significant.
How will your research help patients?  
One goal is to help clinicians assess a patient’s 
risk for vascular disease. Typically when we 
look for common risk factors, we look for LDL 
(low-density lipoprotein) levels and total lipid 
levels. Examining the patient’s inflammatory 
markers gives us more information. High 
levels of inflammatory markers suggest a 
greater risk for vascular disease. 
We are looking at factors that may keep 
patients from forming new vessels efficiently 
and how we can boost the required 
mechanisms to do this. A logical next step 
is to explore the possibility to selectively 
activate the TNFR2, and at the same time 
prevent signaling emanating from the TNFR1. 
This would shift the balance of chronic 
inflammatory signaling and could promote 
a faster recovery after injury.   ■
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3Joseph Rabinowitz, PhD, inserts an ultra high speed 
centrifuge rotor into an ultra centrifuge, where viruses 
are harvested for use in gene therapy.
took special “bioluminescence” images of 
the animals 1, 2, 4, 8 and 12 weeks after the 
injection and measured the photons each 
animal emitted. The imaging revealed various 
levels of expression for the various vectors. 
They next dissected the animal tissue to 
identify which vectors went most readily to 
which organs. Given that AAV9 and AAV6 
were readily observed in the heart, these two 
vectors were identified as most effective for 
gene therapy related to cardiovascular disease.
“Ideally, this would lead to doctors injecting 
cells in a diseased area — such as the heart or 
lungs — with the vector that is most effective 
for that organ,” says Dr. Rabinowitz. “This 
therapeutic gene, once unloaded, supports 
the cell in producing a functional protein 
that counteracts the disease.” The hope is 
that one day, this research will translate into 
gene therapy to combat the high rate of heart 
disease worldwide. ■
Targeting Viruses
Continued from previous page
Glycemic control is a delicate balancing act for 
people managing their diabetes at home, and the 
same is true for physicians treating diabetic patients 
in the Intensive Care Unit (ICU). Particularly 
with insulin-dependent diabetes, the goal of 
keeping blood sugar levels in a healthy range 
is a complicated matter. Too little insulin can 
result in hyperglycemia or high blood sugar levels; 
too much insulin can result in hypoglycemia, or 
low blood sugar levels. Hypoglycemic incidents 
can be fatal, especially in critically ill patients.
This year, the American Association of Clinical 
Endocrinologists (AACE) and the American 
Diabetes Association (ADA) have revised the 
glucose targets for ICU patients, in an effort to 
reduce hypoglycemic incidents and morbidity. 
Jefferson’s Division of Endocrinology is well 
positioned to implement the changes thanks to 
the Jefferson Insulin Infusion Protocol (JIIP), 
first developed in 2005. 
The JIIP protocol has recently translated into 
dramatically improved patient outcomes. 
Jefferson has among the lowest incidence of 
hypoglycemia — less than 1 percent, whereas 
most health care centers are in the range of 
5 to 20 percent. 
Jefferson’s endocrinology team is led by Serge 
Jabbour, MD, Associate Professor of Medicine, 
and Kevin Furlong, DO, Clinical Assistant 
Professor. In 2005, they realized the need for a 
standardized approach to glycemic control of 
New Protocols for Hospital Patients with Diabetes 
Mean Better Outcomes
Endocrinology
ICU patients and began to develop the JIIP in 
collaboration with the Departments of Pharmacy 
and Nursing; JeffIT; the ICU team; and Paul 
Marik, MD, former Director of the Division of 
Pulmonary and Critical Care.
Advances in technology have improved the team’s 
ability to manage glycemic levels. Dr. Jabbour 
explains, “JeffIT created an electronic system that 
allows us to enter a patient’s sugars and obtain 
what change in insulin drip rate is needed.” 
Since the 2009 recommendations and the new 
technology, the team has shown great results — 
less than 1 percent incidence of hypoglycemia.
“Before JIIP,” says Dr. Jabbour, “patients would 
be started on an insulin drip, and the nurse or 
resident would have to do titration and make 
a decision about what was appropriate. Now 
we have one unified protocol for every floor 
of the hospital.”
What was previously considered a correctional 
dose of insulin is also now scaled to the 
individual patient’s needs based on his or her 
body mass index (BMI). “JIIP has also become 
more customized,” explains Dr. Furlong, 
“because a patient with type-1 diabetes who 
weighs 90 pounds responds more dramatically 
to 2 units of insulin drips than a patient with 
type-2 diabetes who weighs 250 pounds.” 
While the JIIP has helped tremendously with 
diabetes care in the ICU, glycemic control still 
is not easy. “What would be ideal,” says Dr. 
Jabbour, “would be a continuous glycemic 
monitor, much like the oxygen monitors that 
we use now, which merely clip onto a finger 
like a clothespin.” He explains that the current 
finger-stick method to monitor blood sugars 
is too invasive and infrequent to do real-time 
monitoring. He hopes that real-time monitoring 
will be the next step for the JIIP. Jeffrey Joseph, 
MD, Director of the Jefferson Artificial Pancreas 
Center, is developing real-time glucose sensors. 
To date, clinical trials have been encouraging. ■
Endocrinology’s Serge Jabbour, MD (left), and Kevin 
Furlong, DO (middle), study data from the electronic 
patient records system, which has been customized to 
standardize care of inpatients with diabetes.
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4In May the Liver Transplantation Program at 
Jefferson celebrated the 25th anniversary of 
the Delaware Valley’s first liver transplant. 
Michael Donahue, Jefferson’s first liver 
transplant patient, was in attendance at the event. 
“It’s a blessing. I’ve been able to get married, 
have children, have a career — live a normal 
life,” said Mr. Donahue in a KYW interview. 
“It’s truly been a gift of life.” Since that 
operation in 1984, Jefferson physicians have 
performed more than 500 transplants.
Victor J. Navarro, MD, Medical Director of 
the Hepatology and Liver Transplantation 
Program, notes that a successful transplantation 
is the result of coordinated efforts from an entire 
team. “Our four transplant surgeons play a critical 
role,” says Dr. Navarro, “but caring for patients 
with liver disease takes the coordinated work 
of a team of other physicians, nurses, and care 
coordinators throughout the patients’ lives.”  
Five coordinators and a social worker support 
the Hepatology/Liver Transplant program. 
“Before transplant, the Hepatology team works 
with gastroenterologists and other referring 
doctors to evaluate the patient’s liver disease 
through procedures such as endoscopies 
and biopsies,” Dr. Navarro explains. In 
cases involving liver cancer, physicians 
State-of-the-Art Liver Transplant Care Celebrates 25 Years
Hepatology
from Interventional Radiology and Medical 
Oncology also consult. Using a liver tumor 
management system that Jefferson developed, 
the team aims to treat the tumor and control 
growth so that the patient is strong enough 
for transplant. “Dr. Edith Mitchell, the 
team’s medical oncologist, has helped provide 
innovative chemotherapies, making the program 
a beacon for other institutions,” says Dr. 
Navarro. “Patients from around the tri-state 
area with liver cancers are coming to us for 
evaluation for transplant.” 
After transplant, the division of GI and 
Hepatology provides a great deal of patient 
care to manage any complications, look for 
signs of infection or rejection, educate the 
patient on home care, and follow up at regular 
intervals for years to come. 
Keeping Jefferson on the leading edge of liver 
patient care also requires excellent research 
and education. To this end, Jefferson is one of 
only 22 institutions in the country to provide a 
Celebrating the 25th anniversary of the Delaware Valley’s 
first liver transplant, Michael Donahue, the transplant 
recipient, remains healthy and active today. Left to right: 
Robert Barchi, MD, PhD, TJU President; Cataldo 
Doria, MD, PhD, Director, Division of Transplantation; 
Mr. Donahue; R. Anthony Carabasi, MD; Tom Lewis, 
Hospital President and CEO; Victor Navarro, MD, 
Medical Director of Liver Transplantation; and 
Charles J. Yeo, MD, Chair of Surgery.
one-year liver transplant hepatology fellowship 
that is approved by the Accreditation Counsel 
for Graduate Medical Education.
In research, the division is currently conducting 
two NIH-funded studies. The first is exploring 
a botanical called silymarin (extracted from milk 
thistle) that is thought to benefit non-alcohol 
induced steatohepatitis and hepatitis C, both 
of which involve inflammation of the liver. This 
is a five-year clinical trial, now in its third year. 
The other NIH-funded study is in drug-induced 
liver injury, meaning liver injury caused by 
bad reactions to commonly prescribed drugs. 
Patients with drug-induced liver injury are 
enrolled and their reaction to a medication, 
herbal, or dietary supplement is carefully studied. 
With its strengths in liver-patient care, 
top-notch hepatology and transplant education, 
and nationally funded research, the Jefferson 
Hepatology/Liver Transplant program is 
positioned to continue its role as a regional 
leader in this critical area of care. ■
Department Chair Arthur Feldman, 
MD, PhD (far left), welcomed Christine 
Seidman, MD, Professor of Medicine and 
Genetics at Harvard Medical School, as the 
45th Annual Martin E. Rehfuss Lecturer on 
April 30, 2009. The title of Dr. Seidman’s 
lecture was “Hypertrophic Cardiomyopathy 
(HCM): A Conversation between Myocytes 
and Fibroblasts.” Dr. Seidman researches 
the causes of HCM, a disease in which the 
heart muscle becomes thickened, a condition 
that can lead to sudden cardiac death. Her 
work, done in partnership with her husband 
Jonathan Seidman, PhD, helps to improve 
diagnosis, provide prognoses, and aid 
sudden death risk stratification. The annual 
Rehfuss lecture honors the late Dr. Rehfuss, 
a Jefferson Medical College faculty member 
who gained an international reputation for 
his research on the digestive system. Dr. 
Rehfuss served as an emeritus professor 
until his death in 1964. ■
45th Annual Martin E. Rehfuss Lecture
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H o w  t o  G i v e
Built on a foundation of compassion and 
first-rate care, Jefferson is committed to 
discovery, innovation, and learning. One 
of only 125 academic medical centers in 
the U.S., we strive to go beyond providing 
exceptional care as we work to break the 
boundaries of our patients’ illnesses.
Learn how you can support this important 
work with a gift to Jefferson. Please contact 
Margaret Fala, Director of Development for 
Medicine, at 215-955-7556 or by e-mail at 
Margaret.fala@jefferson.edu.
Lisa Marie DiRusso (left) ran 15 miles to 
Jefferson to deliver $1,100 in donations in 
memory of her stepfather, who had been a 
liver transplant recipient. Calling her run the 
“Jog to Jeff for John,” Ms. DiRusso decided 
to support research by Victor J. Navarro, MD, 
Medical Director of the Hepatology and 
Liver Transplantation Program (see article, 
page 4). She is shown here with Jefferson 
Development Director Margaret Fala. ■
Jog to Jeff for John
Peter Scarperi of Newtown, Pa., has made a 
generous pledge to support cardiology research 
in the Department’s Center for Translational 
Medicine. His interest grows out of decades 
of experience working for some of the world’s 
most prominent health care corporations.
Mr. Scarperi says that the foundation for his 
personal and professional values is what he calls 
“the three Js”: the Jesuits (he attended St. Peter’s 
College, the Jesuit College of New Jersey) and 
the pharmaceutical giant, Johnson & Johnson, 
where he spent the first 20 years of his career. 
As Chief Financial Officer of McNeil, a 
Johnson & Johnson subsidiary, Mr. Scarperi 
was part of the team that managed the 1982 
Tylenol tampering crisis. A complete product 
recall of 31 million bottles was ordered when 
the company learned that some capsules had 
been injected with cyanide, resulting in seven 
deaths. Thanks to decisive action, including the 
first tamper-resistant packaging, the company 
regained the public’s trust and Tylenol 
returned to its market share within one year 
as the leading over-the-counter painkiller. 
“Our response all came down to the credo 
handed down from founder Robert Wood 
Johnson,” says Mr. Scarperi, “that our first 
and most important responsibility was to our 
customers. I learned firsthand the value of 
translating such strong values into action.” 
Mr. Scarperi also held executive positions at 
the international advertising firm Ogilvy & 
Mather and Nelson Communications. He 
A Health Care Industry Veteran Is 
Inspired to Support Jefferson Research
credits his experience at Johnson & Johnson 
with guiding him throughout his career, and  
notes that these same principles also inform 
his decisions today as a philanthropist.
Mr. Scarperi began his relationship with 
Jefferson in 2008, when he was looking for a 
cardiologist. Through colleagues, he learned 
of the excellent reputation of Howard Weitz, 
MD, Chief of Cardiology and Director of the 
Jefferson Heart Institute. “I was blown away 
by how terrific he was,” Mr. Scarperi recalls, 
“and I was also inspired by all that the 
Department of Medicine was doing.” 
When Mr. Scarperi expressed interest in 
supporting research, the Department arranged 
a meeting with Thomas L. Force, MD, the 
James C. Wilson Professor of Medicine and 
Clinical Director of the Department’s Center 
for Translational Medicine. Mr. Scarperi 
invited his daughter, Sheryl Bunca — who 
worked for Merck & Co. — to accompany 
him, and discovered that Dr. Force and his 
daughter were already acquainted. Pleased by 
the coincidence, and even more impressed 
with the work of the center, Mr. Scarperi 
pledged to support Dr. Force’s research. 
Mr. Scarperi is particularly interested in 
supporting research in areas that have affected 
his family, including heart disease, cancer, 
and birth defects. “As in the best health 
care, I strongly believe that relationships are 
extremely important, and I look forward to 
a long and close relationship with Jefferson. 
Peter Scarperi holds a physician’s cane given to him by 
Jefferson in gratitude for his support for cardiology 
research. Now a distinguished award, a physician’s 
cane historically was hollowed and perforated at the 
top. It contained a preparation that allegedly would 
protect the physician from contagion.
G i v i n g  t o  M e d i c i n e
“I’m happy to play a small part in supporting 
advances that we can make today, in order to 
benefit the patients of tomorrow.” ■
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6The Department of Medicine is fortunate to 
benefit from the service of Gregory Kane, MD 
in multiple roles. Since 2006 he has directed 
the Residency Program and served as Vice 
Chair for Education. In 2008 he also assumed 
the position of Interim Director of the 
Division of Critical Care, Pulmonary, Allergic 
& Immunologic Diseases. 
“Divisions tend to go through life cycles,” 
says Dr. Kane, “and Pulmonary has 
undergone significant transitions. I was 
honored when Dr. Feldman asked me to 
step in during this period and ensure that 
Pulmonary continued to live up to our 
highest standards, department-wide, for our 
core missions of education and patient care.” 
He also continues to see patients himself.
A Growing Division and a New 
Joint Initiative 
Since Dr. Kane took the helm in Pulmonary, 
Michael Scharf, MD, Clinical Associate 
A Physician Leader and Educator Wears Two Hats
Under the direction of Gregory Kane, MD, the Residency Program offers individualized career pathway 
experiences. Left to right: Amyn Hirani, MD; Rodrigo Cavallazzi, MD; Urvashi Vaid, MD; Dr. Kane; 
Sneha Thakkar, MD; Rory Bowers, MD; and Ellina Cheskis, MD.
pulmonary arteries — the arteries that supply 
blood to the lungs,” says Dr. Kane. “This 
forces the heart to work harder to pump 
blood through the lungs, and can lead to right 
heart failure.” 
The new program serves patients who 
need specialized care for both heart and 
lung conditions, including access to high 
quality echocardiography, and offers joint 
consultation by Department Chair and 
cardiologist Arthur Feldman, MD, PhD; 
Howard Weitz, MD; and David Wiener, MD, 
of the Jefferson Heart Institute; and Dr. Awsare.
“We also took part in implementing the 
new, department-wide Medical Information 
System of electronic records,” Dr. Kane says. 
“This significant and exciting development 
enables physicians and residents to capture 
standard orders, as well as options for specific 
medications and consistent care hospital-wide, 
while eliminating errors that were more 
common with paper communication.”
Education and Critical Care, Pulmonary, Allergic & Immunologic Diseases
“For example,” says Dr. Kane, “a resident 
aspiring to an office-based practice can 
choose electives that are outpatient-based. 
If the resident is interested in basic science, 
the program works to identify a laboratory 
mentor and a laboratory experience.” Those 
interested in clinical research might do an 
elective at the Annals of Internal Medicine to 
become familiar with the editorial process of a 
major medical publication. Residents seeking 
a career in clinical research can take part in 
the K30 program, led by Pharmacology Chair 
Scott Waldman, MD, PhD, which focuses 
on the critical skills needed to translate basic 
discoveries into clinical treatments, and offers 
a Clinical Research Curriculum Award.
“The redesign of education in Internal 
Medicine is no longer one-size-fits-all,” 
says Dr. Kane. “We wanted to support our 
residents by recognizing that they’re going 
into careers that are quite varied.” 
About 24 residents are on a clinical education 
and leadership track, led by Gretchen Deimer, 
MD, that offers individualized experiences in 
teaching. Ellina Cheskis, MD, finished her 
residency after only two years in the research 
pathway and then went into the lab to do 
research. Resident Sneha Thakkar, MD, spends 
half of her time on clinical rotations and the 
other half on medical informatics, which uses 
technology — such as electronic prescribing 
of pharmaceuticals — to improve care, safety, 
and efficiency in the hospital. Other pathways 
help residents to become a hospitalist or a 
public health specialist. The efforts of the 
residents will be recorded in a new portfolio 
system being developed by Jessica Salt, MD, 
to highlight the career accomplishments of 
Jefferson’s residents.
This education approach has received national 
attention. In November 2008 Dr. Kane and 
Donna Williams, MD, presented a workshop 
on these career pathways at a national 
meeting of program directors as part of 
Academic Internal Medicine Week. “The 
workshop was well received, ” Dr. Kane says. 
“We look forward to continuing to expand 
our offerings for each incoming group of 
talented residents.” ■
Professor, and Elisabeth Carr, MD, Assistant 
Professor, have joined the staff. They join 
Bharat K. Awsare, MD; Sandra Weibel, MD; 
Michael Baram, MD; Salvatore Mangione, 
MD; and Ritu Grewal, MD. 
The Division has recently begun a new 
program in pulmonary hypertension in 
conjunction with the Jefferson Heart Institute 
(JHI). “This serious condition, which involves 
both the heart and lungs, constricts the 
Residency Program Developments 
The Residency program has also seen some 
significant changes under Dr. Kane’s 
leadership. “We are beginning to implement 
new ways of individualizing the residents’ 
training to fit their unique career interests,” 
says Dr. Kane. A set of nine pathways has 
been developed, so that after the first year of 
residency, which offers core training, residents 
can choose from a series of electives that are 
customized to their particular career focus. 
6
Jefferson Translations, Vol. 4 [2010], Iss. 2, Art. 1
http://jdc.jefferson.edu/translations/vol4/iss2/1
7The Critical Cooperation of Physicians
From the outset, Dr. Feldman highlighted the 
critical role and accountability of the attending 
physicians in general, and the Division Directors 
specifically. To prepare to implement the 
recommendations, he worked with his nine 
Division Directors to identify a “physicians’ 
champion” within the four key in-service teams, 
to shepherd the process on a day-to-day basis. 
Key Recommendations and Implications  
In February of this year, Dr. Feldman convened 
a biweekly LOS multidisciplinary working 
group to implement the recommendations. Of 
the many recommendations and procedural 
changes, the following were identified as key:
1. Huddle Rounds
Each of the four multidisciplinary service teams 
meets by 8:30 a.m., with the primary goal of 
writing discharge orders by 10:00 a.m. for 
patients scheduled to go home that day. The 
huddle also reviews the team’s other patients 
and is proactive regarding newly admitted 
patients as well as those scheduled for discharge 
the following day. Vice President for Clinical 
Resource Management Patrice Miller, BSN, 
MSN, MBA, and her chief manager, Mary 
O’Brien, have been particularly committed to 
making this process work.
“At the conclusion of huddle rounds, all team 
members know specifically what they need 
to do to facilitate timely patient discharge 
and are free to engage in Teaching rounds, 
which must also be completed by 10:00 a.m.,” 
explains Dr. Feldman.
The changes also improve communications 
with each patient. Doctors making rounds 
now must routinely tell new patients on their 
first day in the hospital what their expected 
LOS is. “This helps patients to understand the 
‘big picture’ and to organize any family support 
needed for transport home from the hospital 
as well as follow-up care,” says Ms. Javie.
2. Leveraging Technology
JeffIT’s role has improved the access and 
usability of patient charts. Jeffrey Riggio, MD, 
worked with Mary McNichol in Information 
Systems to include a working LOS in the 
patient’s electronic file. This in turn generates 
a report with a suggested LOS that the team 
uses as a working target.
3. Residents’ Daily Report
The house staff assigned to the teams also 
keeps a daily log of any issues that might 
contribute to an increased LOS and strives 
to coordinate this data into a single report. 
Ms. Javie notes that former chief residents 
David Aziz, Tamara Fisicaro, and Stephanie 
Moleski were instrumental in guiding and 
implementing this aspect of the initiative. 
“This information provides a roadmap for the 
hospital to prioritize systems and to identify 
policies that need to change to support 
appropriate LOS,” says Ms. Javie.
4. Geographic Placement
“Jefferson’s patient placement protocol needed 
updating and an emphasis on management,” 
says Ms. Javie. Joe Anton, Director of Patient 
Logistics, continues to work closely with bed 
placement to assure that patients for various 
services are admitted to the appropriate areas. 
“This is a more consistent way to manage the 
process,” Ms. Javie notes. “It promotes teamwork 
while increasing efficiency by minimizing the 
need for rounds to travel to multiple units.”
Additional Challenges 
In July 2009, the Academic Council on 
Graduate Medical Education (ACGME) 
reduced the number of patients that residents 
and interns are allowed to manage — from 16 
to 14. ACGME also decreased the number of 
attending physicians that any single resident 
would interact with during each day. “To 
comply with the ACGME, we had to create 
a new Hospitalist-run service, consisting of 
our in-hospital specialist physicians and nurse 
Length-of-Stay
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The oversight committee for the LOS initiative: (front row, from left) Sharon Millinghausen, RN, MSN, 
Vice President, Medicine/Cardiac/Critical Care and Specialty Services; Mary Ann McGinley, PhD, RN, Senior 
Vice President and Chief Nursing Officer; Arthur Feldman, MD, PhD, Medicine Chair; Jeffrey Riggio, MD, 
Information Systems and Patient Safety; Tamara Fisicaro, MD, former Chief Resident; (back row, from left) 
Mary McNichol, Information Systems; Michelle Russo, Rehabilitation Medicine; Robin Becker, RPh, MS, 
Pharmacy; Karen Javie, RN, MSN, Vice President for Strategic Initiatives; Michael Rufo, Strategic Initiatives; 
Mary O’Brien, Clinical Resource Management; and Reetika Kumar, MD, Internal Medicine.
practitioners instead of residents,” explains 
Ms. Javie. The next major focus is the creation 
of clinical pathways and order sets for our top 
three Opportunity Medicare Severity Diagnosis 
Related Groups (MS-DRGs). “This patient 
classification system identifies resources needed
as part of the prospective payment system 
required by Medicare,” she says. The other 
insurers have followed Medicare’s lead.
Perspectives to Date
The feedback from every division has been 
extremely positive so far. Physicians and other 
team members claim that the huddles and new 
schedule decrease the number of phone calls 
required and make overall communication much 
easier. Howard Weitz, MD, Director of the 
Division of Cardiology and the Jefferson Heart 
Institute, was impressed: “This was the first time 
in my 30-plus years at Jefferson that I’ve seen 
rounds completed by 10 a.m.,” he says. “This 
new, consistent approach is advantageous to all 
members of the team.” 
“The systemic planning and feedback of 
this initiative draw upon the talents of all 
players,” Dr. Feldman says. “It not only 
maximizes efficiency, but also trains 
physicians in best practices and ultimately 
empowers us to offer our patients the very 
best in coordinated care.” ■
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F a c u l t y  N e w s
New Faculty
The following faculty members have joined the 
Department of Medicine as of January 2009:
Cardiology: Danielle Duffy, MD
Endocrinology: Monica Shirodkar, MD
Gastroenterology: Monjur Ahmed, MD
Hematology: Douglass Drelich, MD; 
Srikanth Nagalla, MD
Internal Medicine: Gustavo Batista, MD;
Mary Halak, MD; Tamara Stolz Solitro, MD
Nephrology: Stephanie DeLoach, MD
Pulmonary: Elisabeth Carr, MD; Michael 
Scharf, MD
Rheumatology: Fabian Mendoza Ballesteros, MD
Center for Translational Medicine: 
Kazi Islam, PhD
The new division of Hospital Medicine was 
created in July 2009. We welcome Susan 
Krekun, MD, Director; Kashif Alauddin, MD; 
Loren Chen, MD; Dani Choufani, MD; Arif 
Hussain, MD; Austin F. Hwang, MD; Keith 
Leung, MD; Anthony Macchiavelli, MD; 
Lalkrushna Malaviya, MD; Melanie Wijetunga, 
MD; Lim Wong, MD.
Each year, the Jefferson Medical College senior 
class commissions a portrait to honor a faculty 
member as an outstanding individual, supportive 
teacher, and inspirational leader. This year’s 
honor went to Joseph A. DeSimone, Jr., MD, 
Clinical Assistant Professor of Medicine and 
Director of the Infectious Disease Fellowship 
Program. The portrait, by artist Joseph Q. Daily, 
is on view on the first floor of Alumni Hall. 
The Pennsylvania Chapter of the American 
College of Physicians has presented Howard 
Weitz, MD, Director of the Division of 
Cardiology and the Jefferson Heart Institute, 
with the Laureate Award for exceptional service 
to his patients, community, and profession. A 
nationally known clinician and educator, Dr. 
Weitz has been at Jefferson for over 30 years.
Wolfgang Bergmeier, PhD, 
received the Kenneth M. 
Brinkhous Young Investigator 
Prize in Thrombosis, which 
recognizes outstanding 
endeavors by new investigators 
in fundamental and applied 
research in thrombosis. Dr. 
Bergmeier is Assistant Professor of Medicine, 
Division of Hematology/Cardeza Foundation 
Hemophilia Center.
A study published recently in the journal 
Circulation by Walter J. Koch, PhD, Director 
of the Center for Translational Medicine, and 
his team, led by Giuseppe Rengo, MD, showed 
that long-term gene therapy resulted in improved 
cardiac function and reversed deterioration of 
the heart in rats with heart failure.
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